Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 0 | -2M | -1M | -3M | -2M |
| EBITDA | 0 | -2M | -1M | -3M | -2M |
| Net Income | 0 | -2M | -1M | -3M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.40
+0.00% today
1Y Change
+536.36%
Window
Jun 23, 2025 → Jun 11, 2026
Coverage: 241 bars · Jun 23, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Raphael Pharmaceutical Inc. (RAPH) is a Healthcare stock with a market cap of $30.00M and listed on OTC. The stock last traded around $1.40 and up 536.4% across the available one-year price window (Jun 23, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +186.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +186.1%, free cash flow +60.5% with operating margin 0.0% and ROIC 79.1%. Stock Foundry combines RAPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RAPH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RAPH Max Drawdown
-97.14%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RAPH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$1.6M
+51.6% YoY
Free Cash Flow
-$1.4M
-86.3% YoY
Revenue Growth
+0.0%
EPS Growth
+186.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 0 | -2M | -1M | -3M | -2M |
| EBITDA | 0 | -2M | -1M | -3M | -2M |
| Net Income | 0 | -2M | -1M | -3M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 45K | 19K | 230K | 288K | 153K |
| Total Assets | 53K | 27K | 239K | 333K | 422K |
| Total Liabilities | 1M | 769K | 132K | 227K | 294K |
| Shareholder Equity | -1M | -742K | 107K | 106K | 128K |
| Total Debt | 0 | 41K | 0 | 0 | 0 |
| Net Debt | -45K | 22K | -230K | -288K | -153K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
-86.8% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
1M
-86.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
102.3%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.